Role of circulating tumor cells in diagnosis of lung cancer: a systematic review and meta-analysis

Zhao, Qingtao; Zheng, Yuxin; Wang, Huien; Zhang, Hua; Duan, Guochen; Zhang, Xiaopeng

doi:10.1177/0300060521994926

Cited by 9 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pooled sensitivity and specificity were 0.72 (95% CI: 0.65–0.79) and 0.96 (95% CI: 0.91–0.98), respectively, and the pooled positive and negative likelihood ratios were 16.86 (95% CI: 7.65–37.12) and 0.29 (95% CI: 0.23–0.37), respectively. Zhao and colleagues concluded that CTCs had good diagnostic value for detecting lung cancer ( 190 ).…”

Section: Future Perspectivementioning

confidence: 99%

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update

et al. 2022

View full text Add to dashboard Cite

Despite efforts to improve earlier diagnosis of non-small cell lung cancer (NSCLC), most patients present with advanced stage disease, which is often associated with poor survival outcomes with only 15% surviving for 5 years from their diagnosis. Tumour tissue biopsy is the current mainstream for cancer diagnosis and prognosis in many parts of the world. However, due to tumour heterogeneity and accessibility issues, liquid biopsy is emerging as a game changer for both cancer diagnosis and prognosis. Liquid biopsy is the analysis of tumour-derived biomarkers in body fluids, which has remarkable advantages over the use of traditional tumour biopsy. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) are two main derivatives of liquid biopsy. CTC enumeration and molecular analysis enable monitoring of cancer progression, recurrence, and treatment response earlier than traditional biopsy through a minimally invasive liquid biopsy approach. CTC-derived ex-vivo cultures are essential to understanding CTC biology and their role in metastasis, provide a means for personalized drug testing, and guide treatment selection. Just like CTCs, ctDNA provides opportunity for screening, monitoring, treatment evaluation, and disease surveillance. We present an updated review highlighting the prognostic and therapeutic significance of CTCs and ctDNA in NSCLC.

show abstract

Section: Future Perspectivementioning

confidence: 99%

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The frequency of cervical lymph node involvement in patients with LC ranges from 1.5% to 32% 11 . LC represents the first cause of death for cancer in men and the third in women 12 . Despite advances in diagnosis and treatment, 5‐year survival is 15% 13 .…”

Section: Discussionmentioning

confidence: 99%

Laterocervical lymph node metastases from suspected thyroidal primary site that turned out to be metastases of lung cancer: A case report

Scorziello,

Borcea,

Biffoni

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageIncidental sonographic discovery of thyroid nodules is an increasingly common event in clinical practice. Less frequently, patients with cytological benign thyroid nodules have suspicious cervical lymph nodes detected by ultrasound examination or by cytological exam. Here, we discuss an intriguing case of cervical lymph node metastasis with a probable thyroid origin in a 65‐year‐old asymptomatic male smoker. He underwent thyroidectomy and unilateral cervical lymphadenectomy. Despite a negative chest X‐ray, the postoperative histological examination revealed that the lymph node metastasis was actually from a lung carcinoma. Metastatic lesions in cervical lymph nodes from non‐thyroidal origins must be excluded when evaluating lesions in the region, especially when thyroid nodules subjected to fine needle aspiration biopsy yield negative results, or lymph node cytological evaluations are inconsistent with thyroid cytological findings and sonographic features. Thyroid and lung adenocarcinomas share some epithelial and mesenchymal markers. Thyroglobulin helps differentiate primary thyroid tumors from lung ones, but in cases of poor differentiation, distinguishing metastatic lesions in the thyroid gland can be challenging. Lung cancer (LC) is the leading cause of cancer mortality worldwide, and survival rates have only marginally improved over the last several decades. The ongoing clinical challenge is detecting LC at earlier stages of the disease.

show abstract

“…The preliminary results indicated that when both CNHC-malignant and CNHC-uncertain were considered positive results, the sensitivity and specificity of CTCs as a biomarker for lung cancer detection were 26.3% (95% CI 11.8-48.8) and 96.2% (95% CI 94.4-97.5) at baseline 113 . Furthermore, a meta-analysis of 21 studies with 3,997 participants has assessed the overall diagnostic accuracy and reported a pooled sensitivity and specificity of 0.72 (95% CI 0.65-0.79) and 0.96 (95% CI 0.91-0.98), thus indicating that CTCs also perform well in the diagnosis of lung cancer 114 .…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

Advances in lung cancer screening and early detection

Wang

Jiang

et al. 2022

Cancer Biol Med

View full text Add to dashboard Cite

Lung cancer is associated with a heavy cancer-related burden in terms of patients’ physical and mental health worldwide. Two randomized controlled trials, the US-National Lung Screening Trial (NLST) and Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON), indicated that low-dose CT (LDCT) screening results in a statistically significant decrease in mortality in patients with lung cancer, LDCT has become the standard approach for lung cancer screening. However, many issues in lung cancer screening remain unresolved, such as the screening criteria, high false-positive rate, and radiation exposure. This review first summarizes recent studies on lung cancer screening from the US, Europe, and Asia, and discusses risk-based selection for screening and the related issues. Second, an overview of novel techniques for the differential diagnosis of pulmonary nodules, including artificial intelligence and molecular biomarker-based screening, is presented. Third, current explorations of strategies for suspected malignancy are summarized. Overall, this review aims to help clinicians understand recent progress in lung cancer screening and alleviate the burden of lung cancer.

show abstract

Role of circulating tumor cells in diagnosis of lung cancer: a systematic review and meta-analysis

Cited by 9 publications

References 42 publications

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update

Laterocervical lymph node metastases from suspected thyroidal primary site that turned out to be metastases of lung cancer: A case report

Advances in lung cancer screening and early detection

Contact Info

Product

Resources

About